Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Eli Lilly and Company is conducting a clinical study titled ‘A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obstructive Sleep Apnea and Obesity or Overweight.’ The study aims to evaluate the efficacy and safety of orforglipron in individuals with moderate-to-severe obstructive sleep apnea (OSA) who are either obese or overweight. This research is significant as it targets a population with limited treatment options, especially those unable or unwilling to use positive airway pressure (PAP) therapy.
The intervention being tested is Orforglipron, an experimental oral drug, compared against a placebo. The purpose of Orforglipron is to provide a new treatment avenue for individuals with OSA and obesity or overweight, potentially improving their quality of life.
This is an interventional, Phase 3 study with a randomized, parallel assignment. It employs a double-blind masking approach, meaning both participants and investigators are unaware of whether the active drug or placebo is being administered. The primary purpose of the study is treatment-focused.
The study officially started on October 22, 2024, with its primary completion estimated for a future date. The most recent update was submitted on July 22, 2025. These dates are crucial as they mark the progression and current status of the study, which remains active but not recruiting new participants.
The outcome of this study could significantly impact Eli Lilly’s stock performance, as a successful result may enhance investor confidence and market position in the sleep disorder treatment sector. Competitors in the pharmaceutical industry will likely monitor these developments closely, as they could shift market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.